X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26) Misses $(0.16) Estimate
X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26) Misses $(0.16) Estimate
X4 Pharmicals 2024 年第一季度公認會計准則每股收益 (0.26) 未達預期 (0.16) 美元
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.16) by 62.5 percent. This is a 62.5 percent decrease over losses of $(0.16) per share from the same period last year.
X4 Pharmicals（納斯達克股票代碼：XFOR）公佈的季度虧損爲每股0.26美元，比分析師普遍預期的0.16美元（0.16美元）低62.5％。這比去年同期每股虧損0.16美元（0.16美元）下降了62.5％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。